Navigation Links
Mach One Corporation Files its Form SB-2 with the SEC
Date:10/16/2007

LAS VEGAS, Oct. 16 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN) is proud to announce that it has filed its SB-2 registration with the Securities and Exchange Commission. The company had announced previously its intention of becoming a fully reporting company under the 1934 Act, and today made it official. The company is next filing to be listed on the OTCBB following the effectiveness of the SB-2. "This is a monumental day for Mach One; we are now poised to move forward as fully reporting company with the next step -- the OTCBB," said Monte Tobin, CEO of Mach One. "Upon the effectiveness of the registration, we will make a public announcement for the benefit of our shareholders and future shareholders.

Mach One Corporation is currently trading on the Pink Sheets, under the symbol MNCN. Upon the effective date of the filing, the Company will attain Section 12 (g) reporting status with the SEC, under the Exchange Act of 1934, which will allow for broader market participation in the Company's shares by institutional investors. As a reporting company, Mach One Corporation will be required to file annual reports on Form 10-KSB, quarterly reports on Form 10-QSB, and reports of unusual events on Form 8K. In addition, the Company will be required to solicit proxies for its annual meetings in accordance to Section 14 of the Securities Exchange Act of 1934 and other reporting requirements will apply to management shareholdings.

Investors can view the filing by accessing the SEC's website at http://www.sec.gov.

About Mach One Corporation

The company (http://www.machonecorp.com) specializes in Immune or Gamma Globulin replacement (IgG) for the equine and bovine markets. Through it's subsidiary company VDx, Inc., the company plans full scale manufacturing and distribution of Immunogam(TM), a colostrums replacement, supplement
'/>"/>

SOURCE Mach One Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. Novartis files application with FDA for Zometa
3. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
4. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
5. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
6. Personality profiles of gamblers and substance abusers are similar
7. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
8. Venus Remedies Files 5th International Patent Application
9. Shoaib Akhtar files appeal against ban
10. AIIMS Official Files Complaint Against Venugopal
11. Glaxo Files Cancer Drug For Approval With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...ath the lining of the uterus (submucosal) are more...erine artery embolization (UAE) but usually dont c.... , The study included 49 patients with 140 fib...after UAE. The study found that 39 of these were s...al cavity after UAE, said Sachit Verma, MD, lead a...
(Date:5/16/2008)... May 19 at 10:15 a.m. Eastern Time, VANCOUVER, Ma...Corporation (TSX: RBM, OTCBB: RPBIF) today announc...scheduled to present at the Rodman & Renshaw,5th A...9th at 10:15 a.m.,EDT., A live web cast of the pr...site at, http://www.responsebio.com/newsroom_event...
(Date:5/16/2008)...d benefit most from chemo after surgery, study say... A panel of 15 genes may help determine which pati...ill experience a recurrence and, therefore, benefi..., By extension, the same genetic signature may ...of the cancer who would be able to forego chemothe...
(Date:5/16/2008)...udents learn the lesson of helping others ...NJING, China, May 16 /PRNewswire/ -- In the afterm...e youngest members of China are,looking for ways t...und the,country, schools are running donation driv... principal, Ms. Zhang Lijun, the 190-student stron...
Breaking Medicine News(10 mins):Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Chinese Preschoolers Participate in Fund Drive to Help the Victims of Sichuan Quake 2
...dy and you are on a dieting course, there might be...searchers. Nutrition scientists from// Arizona Sta...in the body has a direct relation with the lower b...min C in the blood stream, it could cause increase...
...the risk of obesity, say scientists. Researcher Vi...ice in children’s diet and body mass index (BMI) o...nclusion. // According to foodconsumer.org, he f...cantly lower z-scores for body mass index for thei...
...s been found that children who have the habit of w...han if they don't watch. // And it has also been f... of watching TV during lunchtime, ate comparativel...ows. Dr. Lori Francis, assistant professor of biob...
... health emergencies like predicting about the deve...cientists have devised a simulator, which could ma...bird flu pandemic based on today's environment of ...m of scientists from Los Alamos National Laborator...
Other Medicine News:Health News:Vital Facts of Short Term Diets - Catch The Vitamin Behind An Ample Waist! 2Health News:Viewing TV During Lunch Affects Children's Food Intake 2Health News:Supercomputers To Assist In Thwarting Bird Flu Epidemic In Future 2Health News:Supercomputers To Assist In Thwarting Bird Flu Epidemic In Future 3Health News:Supercomputers To Assist In Thwarting Bird Flu Epidemic In Future 4
(Date:5/16/2008)...DGEWATER, N.J., May 16 /- Data from t... mean baseline hemoglobin (Hb) levels,and the rate...fect of,restrictions on reimbursement for erythrop...nts on the nation,s blood supply, will be presente...CO) Annual Meeting later this,month. The meeting w...
(Date:5/16/2008)...,s Technology Enables First-Ever PEGylation of a S...Therapeutic Activity, SAN CARLOS, Calif., May 16 ...daq: NKTR ) announced initial results today from .... The data shows significant,anti-tumor activity i...,also demonstrates that Nektar,s small molecule PE...
(Date:5/16/2008)...le Molecule with Dual Mechanism May Offer Novel Ap...Management, NEW ORLEANS, May 16 /PRNewswire-First... in the discovery and development of novel small,m...0, its first-in-class,Dual Acting Receptor Antagon... pressure reductions in a Phase 2a study in patien...
(Date:5/15/2008)...DCLIFF LAKE, N.J., May 15 /- Eisai Co...sults from 16 clinical data abstracts about,compou...rtfolio and,preclinical oncology research have bee...ting of the American Society of Clinical Oncology ...e 3, 2008., A wide variety of abstracts on Eisai ...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Angiotech to participate in Lehman Brothers Healthcare Conference 4021 1Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 1Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 2Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 3Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 4Clovis age overkill didnt take out Californias flightless sea duck 2530 1Clovis age overkill didnt take out Californias flightless sea duck 2530 2USP Announces Revised Glycerin Monograph 4019 1USP Announces Revised Glycerin Monograph 4019 2USP Announces Revised Glycerin Monograph 4019 3
The NOW® Malaria Test is a field or laboratory test for the differential diagnosis of a Malaria infection. It is intended for the detection of circulating Plasmodium falciparum (P.f.) antigen
...re Monitor (PCM) and Central Station provide an ex...nds the cardiac cath or electrophysiology lab to h...or EP procedures, providing both physiomonitoring ...either standalone or on its own network. Witts Cen...
For the critical care environment, telemetry, emergency room and other monitoring areas.
DS 7600 Central Station
Medicine Products: